Fiedler, Timon
Fairless, Richard
Pichi, Kira
Fischer, Roman
Richter, Fabian
Kontermann, Roland E.
Pfizenmaier, Klaus
Diem, Ricarda
Williams, Sarah K.
Funding for this research was provided by:
Deutsche Forschungsgemeinschaft (FOR2289)
Universitätsklinikum Heidelberg
Article History
Received: 1 February 2023
Accepted: 20 April 2023
First Online: 30 April 2023
Declarations
:
: All animal work was performed in accordance with European and German animal protection law with approval from the ‘Regierungspräsidium’ in Karlsruhe, Germany (AZ. 35-9185.81/G-203/17).
: All authors have approved the manuscript submission.
: KPf, FR and REK are named inventors on a patent covering the TNFR1 antagonist. KPf, RFi and REK are named inventors on a patent covering the TNFR2 agonist. KPf and REK received funding from Baliopharm, a company which has licensed the TNFR1 technology. REK and RFi received funding from Resano, a company which has licensed the TNFR2 technology.